Clinical trial NCT06160284: Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Official title: Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Opioid Use Disorder
Lead sponsor: Yale University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2023-12-07
Enrollment: 12
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Participants will be medically healthy females and males with OUD.
Primary purpose: BASIC_SCIENCE

Brief summary: This study will examine the synaptotrophic effects of psilocybin among medically healthy, detoxified OUD subjects. Eligible OUD participants will undergo pre- and post- psilocybin administration PET scans with the \[11C\]-UCB-J radiotracer while inpatient.

Detailed description: Participants will undergo screening as outpatients at the Clinical Neuroscience Research Unit (CNRU). Once deemed eligible, OUD subjects will be studied as inpatients. However, they will have the option of scheduling their second \[11C\]-UCB-J PET as an outpatient (pending these participants' agreement to undergo outpatient visits twice per week to provide urine toxicology to monitor abstinence before PET).

The only portion of the study that will be available as outpatient for OUD subjects will be the 1-2 weeks before the second \[11C\]-UCB-J PET scan. The subject will still be admitted for 1-2 weeks, which will include: inpatient detoxification, baseline \[11C\]-UCB-J PET scan, psilocybin administration, and overnight observation after psilocybin administration. However, they may be discharged the day following psilocybin administration and return 2x weekly for urine toxicology testing between discharge and the second \[11C\]-UCB-J PET to confirm abstinence.

Structural magnetic resonance imaging (MRI) scans will be obtained for anatomical registration/partial volume correction from all subjects. Functional MRI (fMRI) scans will be completed pre- and post-psilocybin administration to evaluate changes in resting state connectivity. All subjects will participate in a battery of behavioral assessments for exploratory correlations with \[11C\]-UCB-J. Inpatient subjects who smoke cigarettes will have the option of using nicotine gum and/or nicotine patch while on the unit in order to prevent or minimize nicotine withdrawal. The \[11C\]-UCB-J PET scans will be done at the Yale PET Center 1-2 weeks before (baseline) and after psilocybin administration.

This is a single-center study at Yale, that will have study activities completed at the following areas:

* Clinical Neuroscience Research Unit (CNRU) of the Connecticut Mental Health Center (CMHC)
* Yale Positron Emission Tomography (PET) Imaging Center
* Yale Magnetic Resonance Research Center (MRRC)

Eligibility criteria: Inclusion Criteria:

* Voluntary, written, informed consent;
* Physically healthy by medical history, physical, neurological, ECG, and laboratory examinations;
* DSM-5 criteria for Opioid Use Disorder;
* Documented evidence (by urine toxicology) of opioid use (upon screening);
* Inpatient verified \> 1 week of abstinence;
* For females, a negative serum pregnancy (beta-HCG) test.

Exclusion Criteria:

* DSM-5 criteria for other substance use disorders (e.g., alcohol, cocaine, sedative hypnotics), except for nicotine (concurrent alcohol or drug use is allowed if it does not meet criteria for a substance use disorder and does not take place during inpatient stay)
* A primary DSM-5 Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depression, as determined by psychiatric history (Mini International Neuropsychiatric Interview, MINI), or another disorder that may interfere with the study's primary outcomes in the view of PI
* Immediate (first-degree relative) family history of formally diagnosed schizophrenia or other psychotic disorders (e.g., delusional disorder, schizoaffective disorder), or bipolar I/II disorder
* A history of significant and/or uncontrolled medical or neurological illness
* Hypertension at screening defined as: systolic blood pressure \> 140 mmHg or diastolic blood pressure \> 90 mmHg;
* History of cardiovascular disease, including but not limited to clinically significant coronary artery disease, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, angina pectoris, coronary artery bypass graft or artificial heart valve, stroke, transient ischemic attack, or any clinically significant arrhythmia
* Any clinically significant abnormal electrocardiogram (ECG) finding, such as findings suggestive of ischemia or infarct, complete bundle branch block, atrial fibrillation or other symptomatic arrhythmia, or predominantly non-sinus rhythm, at screening
* Resting QT interval with Fridericia's correction (QTcF) ≥ 450 msec (male) or ≥ 470 msec (female) at Screening, or inability to determine QTcF interval
* Presence of risk factors for torsades de pointes, including: long QT syndrome, uncontrolled hypokalemia or hypomagnesemia, history of cardiac failure, history of clinically significant/symptomatic bradycardia, family history of idiopathic sudden death or congenital long QT syndrome, or concomitant use of a torsadogenic medication
* Current use of psychotropic and/or potentially psychoactive prescription medications considered to the investigators are likely to interfere clinically with human subject's safety (i.e., contraindicated drug-drug interactions with psilocybin) or scientifically (i.e., likely to influence or alter outcomes of the study)
* Medical contraindications to MRI procedures (e.g., ferromagnetic implants/foreign bodies, claustrophobia, etc.)
* Arterial Line Exclusion: Blood donation within eight weeks of the start of the study
* Arterial Line Exclusion: History of a bleeding disorder or are currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)
* Participation in other research studies involving ionizing radiation within one year of the PET scans that would cause the subject to exceed the yearly dose limits followed by the Yale PET Center (21CFR361.1).

Primary outcomes:
measure: Change in Synaptic Density
timeFrame: baseline and 1-2 weeks post treatment
measure: Association between VT and BPND
timeFrame: up to 12 weeks
measure: Time to relapse
timeFrame: up to 12 weeks
measure: Urine toxicology post treatment
timeFrame: up to 12 weeks
Secondary outcomes:
measure: Change in vital signs- heart rate (HR)
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Change in vital signs- respiratory rate (RR)
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Change in vital signs- oxygen saturation
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Change in vital signs- systolic blood pressure
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Change in vital signs- diastolic blood pressure
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Change in vital signs- body temperature
timeFrame: immediately prior to psilocybin treatment with and up to 5 hours+ post treatment
measure: Total number of participants with treatment emergent adverse events
timeFrame: up to 12 weeks
measure: Change in Profile of Mood States (POMS) Score
timeFrame: approximately 30 and 150 minutes post Psilocybin treatment
measure: Change in Clinical Opioid Withdrawal Scale (COWS) Score
timeFrame: approximately 30 and 150 minutes post Psilocybin treatment
measure: Change in Subjective Opioid Withdrawal Scale (SOWS) Score
timeFrame: approximately 30 and 150 minutes post Psilocybin treatment
measure: Change in Opioid Symptom Checklist (OSC)
timeFrame: approximately 30 and 150 minutes post Psilocybin treatment
Other outcomes:
Locations:
city: New Haven
country: United States
facility: Yale University
state: Connecticut
Study officials:
affiliation: Yale University
name: Gustavo Angarita, MD, MHS
role: PRINCIPAL_INVESTIGATOR
References: